Join Growin Stock Community!

Idexx laboratories inc(IDXX.US AI Earnings Summary)

US StockHealthcare
No presentation for IDXX

IDXX AI Earnings Summary (In-Depth)

Last updated: 2026-11-02 (US time)

2026 Q3

Core Highlights

All financial metrics this quarter met or exceeded the previous quarter's guidance.

  • Stock Price Reaction: IDEXX LABORATORIES INC reported strong Q3 results pre-market on November 2, 2026. Boosted by robust performance and an upgrade to full-year revenue guidance, the stock surged 17.2% to $646 in pre-market trading (some reports also noted a 6.1% pre-market gain).
  • Market Expectations: Revenue reached $1.21B, matching the consensus estimate of $1.21B; actual earnings per share (EPS) for the quarter was $4.01.
  • Performance vs. Guidance: All targets met. Reported operating margin was 33.1%, exceeding the upper end of the 32.5%–32.8% guidance by approximately 0.3 percentage points.
  • Bottom Line: Despite a decline in same-store clinic visit volume, the company achieved 10% organic revenue growth driven by innovative product expansion and record high-end instrument placements. The market responded with a pre-market surge of up to 17.2%.

Quarterly Highlights

Innovation platforms are flourishing across the board, with organic growth momentum continuing to accelerate independently of a recovery in clinic visit volume.

  1. Total organic revenue growth of 10%, with CAG Diagnostics recurring revenue organic growth of 11%: Total organic revenue grew 10% YoY this quarter. Specifically, Companion Animal Group (CAG) Diagnostics recurring revenue organic growth was 11%, with 9.6% growth in the US and 14% internationally. For the fourth consecutive quarter, US CAG Diagnostics recurring revenue growth exceeded visit volume growth by over 1,000 basis points, demonstrating that diagnostic utilization has become a growth engine independent of visit volume.

  2. Reported operating margin of 33.1%, exceeding the upper guidance limit by 0.3 percentage points: This quarter's reported operating margin of 33.1% was approximately 0.3 percentage points above the previous guidance range of 32.5%–32.8%. On a comparable basis, this represents a 60 basis point YoY increase, even after absorbing costs related to the CoVet acquisition. Gross margin was 62.9%, up 90 basis points YoY on a comparable basis, benefiting from volume growth in VetLab consumables and high-margin Reference Laboratory business.

  3. EPS of $4.01, up 18% YoY (up 22% on a comparable basis): GAAP EPS was $4.01, an 18% increase YoY; it grew 22% on a comparable basis, partially aided by a $0.03 per share contribution from non-operating gains in equity investments and a $0.04 per share foreign exchange tailwind. External reports indicated that adjusted EPS for the quarter outperformed expectations.

  4. High-end instrument placements hit a Q3 record; cumulative inVue Dx installations near 11,000 units: High-end instrument placements reached 5,780 units this quarter, including 1,904 inVue Dx units, nearly half of which were from international markets. Global cumulative inVue Dx installations have reached nearly 11,000 units, with over 4,600 placed year-to-date. Management confirmed that exceeding the full-year target of 5,500 units is certain, and the five-year goal of 20,000 units remains on track.

  5. Cancer Dx customers surpass 14,000; officially upgraded from a single test to a multi-cancer screening panel: Cumulative ordering customers for IDEXX Cancer Dx exceeded 14,000 this quarter. With the addition of canine mast cell tumor detection in September, Cancer Dx has evolved from a single lymphoma test to a multi-cancer panel, while maintaining its $15 entry price in the US when run alongside blood work. 70% of Cancer Dx tests are performed with blood panels, indicating deep integration into routine clinical workflows.

  6. CoVet acquisition completed; AI-native clinical workflow software has annualized revenue of approximately $20M: IDEXX completed the acquisition of CoVet in September. CoVet is an AI-native ambient listening and clinical workflow software provider with approximately $20M in annualized revenue growing at strong double digits. It has been deployed in the US and over a dozen international markets and is already integrated with ezyVet.

  7. Free cash flow of $421M, totaling $978M year-to-date with a 110% net income conversion rate: Free cash flow reached $421M this quarter, bringing the year-to-date total to $978M. The net income conversion rate over the last twelve months was 110%. The company also repaid $75M in senior notes and deployed approximately $335M in capital through the CoVet acquisition and share repurchases. Year-to-date share repurchases totaled $805M, supporting a 2% YoY decline in diluted shares.

  8. Full-year revenue guidance raised by $32M at the midpoint; EPS guidance raised by $0.25 per share: Driven by strong Q3 performance, full-year revenue guidance was raised to $4.741B–$4.767B, with organic growth expected to reach 9.3%–10%. Full-year EPS guidance was raised to $14.96–$15.16, representing 15%–16% growth on a comparable basis, even after absorbing a $0.13 per share dilution from CoVet.

Sign up for free!

You can sign up for free or Log In to read more information!

Free In-Depth for popular US stocks:

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer